Skip to main content
Clinical Trials/KCT0000950
KCT0000950
Recruiting
未知

Safety and Efficacy of Allogeneic Umbilical Cord Blood Therapy Combined With Erythropoietin in Children With Cerebral Palsy: a Double-blind, Randomized, Placebo-controlled Clinical Trial

Bundang CHA General Hospital0 sites120 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Diseases of the nervous system
Sponsor
Bundang CHA General Hospital
Enrollment
120
Status
Recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional Study
Sex
All

Investigators

Sponsor
Bundang CHA General Hospital

Eligibility Criteria

Inclusion Criteria

  • 1\. Diagnosed with cerebral palsy
  • 2\. Age of \=10 months and \=6 years
  • 3\. Mismatch in HLA\-A, B, and DR \=2, and total nucleated cell count \=3x10^7/kg. If the cell count is less than given values, more than 1 unit could be used.
  • 4\. Hemoglobin \=13\.6 g/dL
  • 5\. Decision of participation in the study by and acquisition of informed consent from the subject’s representative
  • 6\. Willingness and ability to be hospitalized according to the schedule specified in the protocol and continue the study for 12 months after study entry

Exclusion Criteria

  • 1\. Current aspiration pneumonia
  • 2\. Known genetic disease
  • 3\. History of hypersensitivity reaction to any study drugs pertinent to the study
  • 4\. History of participation in any other study with stem cell
  • 5\. Prior treatment with EPO within 3 months prior to study entry
  • 6\. Known coagulopathy with family history of thrombosis or medical history of recurrent thrombosis
  • 7\. Patient with severe seizure disease who has clinical convulsion despite combination therapy with 3 or more agents
  • 8\. Uncontrolled hypertension defined as systolic blood pressure \>115 mmHg and/or diastolic blood pressure \>70 mmHg
  • 9\. Hepatic impairment defined as asparate aminotransferase (AST) \>55 IU/L and/or alanine aminotransferase (ALT) \>45 IU/L
  • 10\. Renal impairment defined as creatinine (Cr) \=1\.2 mg/dL

Outcomes

Primary Outcomes

Not specified

Similar Trials